A Phase 3 interventional study of REKOVELLE (Follitropin Delta) and GONAL-F (Follitropin Alfa) in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 16 sites in 5 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.
Among the 13 studies testing follitropin delta in Infertility, this one is the 5th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 11th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18–38 · Women only
By country, each count listing its studies:
follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2022.
This study's enrollment of 302 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
39 studies in Infertility by Ferring Pharmaceuticals: none open now, 2 under way, none of them phase 3. Of 35 finished, 18 (51%) have results posted.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2022, is one of 11 in phase 3, and was the 32nd registered.
Ferring Pharmaceuticals’s Infertility studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing follitropin delta in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ferring Pharmaceuticals’s 39 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Hormone preparations like REKOVELLE and GONAL-F are used to make the body produce multiple egg sacs, allowing more eggs to be collected from women undergoing infertility treatment.
The main purpose of this trial is to see how many eggs are produced with a starting dose of 15 µg REKOVELLE compared to a starting dose of 225 IU GONAL-F. This research is intended to provide more knowledge about REKOVELLE, including the doses given in the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: REKOVELLE (Follitropin Delta)
Other: GONAL-F (Follitropin Alfa)
REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE was 15 μg fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose could be increased or decreased by 5 μg based on the participant's response. The minimum REKOVELLE dose was 5 μg and the maximum REKOVELLE was 20 μg. Participants could be treated for a maximum of 20 days.
GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 225 IU fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose could be adjusted by 75 IU based on the participant's response. The minimum GONAL-F dose was 75 IU and the maximum GONAL-F dose was 300 IU. Participants could be treated for a maximum of 20 days.
Number of Oocytes Retrieved
The number of oocytes retrieved was recorded at the oocyte retrieval visit.
Time frame: On day of oocyte retrieval (Up to 22 days after start of stimulation)
Number of Follicles (Total) at End-of-stimulation
Counted by transvaginal ultrasound for the right and left ovary for each subject.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Size of the Follicles at End-of-stimulation
Counted by ultrasound for the right and left ovary for each subject.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Serum Concentrations of Estradiol at End-of-stimulation
Blood samples for analysis of circulating concentrations of estradiol were drawn.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Serum Concentrations of Progesterone at End-of-stimulation
Blood samples for analysis of circulating concentrations of progesterone were drawn.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Number of Fertilized Oocytes
The number of pronuclei were counted after insemination. Fertilized oocytes with 2 pronuclei (2PN) were regarded as correctly fertilized.
Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Fertilization Rate
The fertilization rate was defined as the number of oocytes with 2PN divided by the number of oocytes retrieved.
Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Number of Blastocysts and Number of Good Quality Blastocysts
Number of blastocysts and number of good quality blastocysts on Day 5 or 6 were presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.
Time frame: On Day 5 or Day 6 (as applicable) after oocyte retrieval (up to 27 or 28 days after start of stimulation)
Total Gonadotropin Dose
Calculated by start dates, end dates and daily dose of investigational medicinal product (IMP).
Time frame: Up to 20 stimulation days
Number of Stimulation Days
Calculated by start dates and end dates.
Time frame: Up to 20 stimulation days
Proportion of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Overall and by Grade) and/or Preventive Interventions for Early OHSS
Early OHSS is defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.
Time frame: Up to 9 days after triggering of final follicular maturation
| Milestone | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Started | 200 | 100 |
| Completed | 196 | 94 |
| Not completed | 4 | 6 |
The number of oocytes retrieved was recorded at the oocyte retrieval visit.
| Oocytes Retrieved | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Number of Oocytes Retrieved | 9.0 (6.0 to 13.5) | 9.0 (6.5 to 13.0) |
Counted by transvaginal ultrasound for the right and left ovary for each subject.
| Follicles | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Number of Follicles (Total) at End-of-stimulation | 12.0 (9.0 to 16.0) | 12.0 (9.0 to 16.0) |
Counted by ultrasound for the right and left ovary for each subject.
| mm | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Size of the Follicles at End-of-stimulation | 15.7 (14.7 to 16.8) | 16.0 (15.1 to 16.9) |
Blood samples for analysis of circulating concentrations of estradiol were drawn.
| pmol/L | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Serum Concentrations of Estradiol at End-of-stimulation | 6085.0 (3516.0 to 8602.0) | 5853.5 (4053.5 to 9742.0) |
Blood samples for analysis of circulating concentrations of progesterone were drawn.
| nmol/L | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Serum Concentrations of Progesterone at End-of-stimulation | 2.9 (1.9 to 3.8) | 2.5 (1.6 to 3.5) |
The number of pronuclei were counted after insemination. Fertilized oocytes with 2 pronuclei (2PN) were regarded as correctly fertilized.
| Oocytes | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Number of Fertilized Oocytes | 5.0 (3.0 to 8.0) | 5.0 (3.0 to 7.0) |
The fertilization rate was defined as the number of oocytes with 2PN divided by the number of oocytes retrieved.
| percentage of oocytes fertilised | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Fertilization Rate | 54.5 (40.0 to 71.4) | 57.7 (40.0 to 71.4) |
Number of blastocysts and number of good quality blastocysts on Day 5 or 6 were presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.
| Blastocysts | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Number of Blastocysts | 2.0 (1.0 to 5.0) | 3.0 (1.0 to 4.5) |
| Number of good quality blastocysts | 2.0 (1.0 to 4.0) | 2.0 (0.0 to 3.0) |
Calculated by start dates, end dates and daily dose of investigational medicinal product (IMP).
| ug | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Total Gonadotropin Dose | 135 (120.0 to 160.0) | 148.5 (137.5 to 165.0) |
Calculated by start dates and end dates.
| days | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Number of Stimulation Days | 9.0 (8.0 to 10.0) | 9.0 (8.0 to 10.0) |
Early OHSS is defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.
| Participants | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| Early OHSS (any grade) | 5 | 3 |
| Early OHSS (moderate/severe) | 1 | 1 |
| Early OHSS (any grade) and / or preventative interventions | 33 | 17 |
| Early OHSS (moderate/severe) and / or preventative interventions | 30 | 16 |
Collected over 4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| REKOVELLE (Follitropin Delta) | 0/200 (0%) | 0/200 (0%) | 24/200 (12%) |
| GONAL-F (Follitropin Alfa) | 0/100 (0%) | 2/100 (2%) | 11/100 (11%) |
| Event | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| HaemoperitoneumGastrointestinal disorders | 0/200 | 2/100 |
| Event | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) |
|---|---|---|
| HeadacheNervous system disorders | 23/200 | 8/100 |
| Pelvic painReproductive system and breast disorders | 1/200 | 5/100 |
| Age, Continuous(years) | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) | Total |
|---|---|---|---|
| Mean | 34.5 ± 3.8 | 34.5 ± 3.4 | 34.5 ± 3.7 |
| Age, Customized(Participants) | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) | Total |
|---|---|---|---|
| <35 Years | 83 | 43 | 126 |
| 35 - 37 Years | 74 | 39 | 113 |
| 38 - 40 Years | 43 | 18 | 61 |
| Sex: Female, Male(Participants) | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) | Total |
|---|---|---|---|
| Female | 200 | 100 | 300 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 20 | 47 |
| Not Hispanic or Latino | 173 | 80 | 253 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 7 | 0 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 191 | 98 | 289 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | REKOVELLE (Follitropin Delta) | GONAL-F (Follitropin Alfa) | Total |
|---|---|---|---|
| Austria | 46 | 22 | 68 |
| Italy | 35 | 15 | 50 |
| United Kingdom | 29 | 13 | 42 |
| France | 5 | 3 | 8 |
| Spain | 85 | 47 | 132 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Apr 2024, 21 months.
Results were first posted in Apr 2025, 11 months after primary completion.
Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.
Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta